Oncology Round-Up: Ribociclib, “Unheard of” Response in Breast Cancer; and More

Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer

Ribociclib plus endocrine therapy led to a statistically significant improvement in PFS compared with placebo plus endocrine therapy in participants with tumor progression following a CDK 4/6 inhibitor

Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer

Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor activity in patients with HER2-positive advanced or metastatic breast cancer.

“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer

Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated significant survival benefit with trastuzumab deruxtecan versus standard of care chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer.

These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases

Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting revealed prognostic factors that impacted overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases

Sunitinib as Second-Line Metastatic Renal Cell Carcinoma Treatment

In ESMO Open, Enrique Grande, MD, and collaborating researchers published findings from the IMMUNOSUN trial on the safety and efficacy of sunitinib as a pure second-line treatment for patients with metastatic renal cell carcinoma (mRCC).